Experimental cell therapy targets tough blood cancers and anemia
NCT ID NCT07205315
First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 3 times
Summary
This early-phase study is testing a new cell therapy called GT801 in 28 adults with relapsed or hard-to-treat B-cell blood cancers (like leukemia and lymphoma) or autoimmune hemolytic anemia (AIHA). The therapy uses a patient's own immune cells, modified to attack CD19-positive cells. The main goals are to check safety and see if the treatment shrinks tumors or controls the anemia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GT801 Injection (a cell therapy made from the patient's own immune cells, engineered to target CD19-positive cells)
- What this could lead to
- If successful, this could point toward a new treatment option for patients with hard-to-treat B-cell blood cancers and autoimmune hemolytic anemia.
- What could go wrong
- This is a very early (Phase 1) trial with only 28 participants, so it is too soon to know if the treatment is safe or effective. Cell therapies can cause serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, China
-
Zhengzhou Yihe Hospital
ACTIVE_NOT_RECRUITINGZhengzhou, Henan, 450018, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can 3D-Printed models unlock personalized blood cancer therapies?
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Can engineered immune cells tame autoimmune anemia?
- Could a protein blocker quiet Leukemia's alarm system?
- Can targeted drugs blinatumomab and venetoclax improve outcomes for childhood leukemia?
- Supercharged immune cells take aim at cancer and viruses in one shot